News Summaries

China’s Fight Against Brain Injuries: New Research, Treatments, and Hope for Patients

Traumatic brain injury (TBI) remains a leading cause of death and disability in China, but the landscape is shifting. An aging population, the boom of electric scooters and a rise in falls have changed how injuries occur, while faster pre‑hospital care—now bolstered by 5G‑enabled emergency networks—gets patients to hospitals quicker. Chinese researchers are testing bold new therapies: prolonged mild‑hypothermia cooling for severe TBI, median‑nerve electrical stimulation to wake patients from coma, and middle‑meningeal‑artery embolisation for chronic subdural hematomas. At the same time, the nation is building a nationwide trauma‑center network and a multidisciplinary collaboration model to standardise care. Challenges persist, however. Neurosurgeon training is shorter than abroad, and a shortage of specialists creates regional gaps in access to advanced treatment. Chinese guidelines for intracranial‑pressure management differ from Western recommendations, often waiting for higher pressure thresholds before operating. Meanwhile, stroke care under the “Healthy China 2030” plan has seen mortality fall, yet the total number of patients climbs as the population ages. The push toward prevention, AI‑assisted diagnosis, and full‑cycle health management aims to keep the momentum. Together, these advances offer a hopeful roadmap for reducing the burden of brain injuries across the country.

China’s Cancer Trials Speed Ahead – Enrolling Patients 3‑5× Faster and Cheaper Than the West

China has become a global hotspot for oncology drug testing. Recent data show that patient enrollment in Chinese cancer trials is three to five times faster than in Europe or the United States, while the cost per patient is only 20‑30 % of that abroad. This speed comes from a “two‑pronged” model that runs investigator‑initiated studies alongside regulator‑approved new‑drug trials, creating a dense pipeline of more than 8,000 IND trials domestically. In 2025 China’s overseas licensing deals for innovative medicines topped $130 billion, half of the world market, and the trend continued into 2026. The surge has attracted multinational giants: Merck now runs one of only two fully independent R&D centers outside its headquarters in China, and several other global firms have opened multiple Chinese research hubs. Yet public misunderstanding remains a hurdle. Healthy volunteers in Phase I studies are often portrayed as “selling their bodies for cash,” obscuring the rigorous safety standards and vital contributions they make. Leaders like Li Ning of the National Cancer Center stress that changing these perceptions is essential to sustain the momentum. Overall, China’s massive patient pool, concentrated cancer centers, and supportive policies are reshaping the global drug‑development landscape, positioning the country as a premier destination for fast, affordable, and high‑quality clinical research.